Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Real-world use of transthyretin silencers in patients with Val50Met familial amyloid polyneuropathy and cardiac involvement
Session:
Sessão de Posters 12 - Estratégias terapêuticas e desfechos em vida real na ATTR-CM
Speaker:
PEDRO CARVALHO MONTEIRO
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.4 Myocardial Disease – Treatment
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Pedro Monteiro; Tiago Peixoto; Diana Ribeiro; Mariana Pereira Santos; David Sá Couto; Andreia Campinas; Sara Fernandes; Marta Oliveira; Ana Meireles; André Luz; Patrícia Rodrigues
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:11.0pt">Introduction: </span></strong><span style="font-size:11.0pt">RNA-targeted transthyretin (TTR) silencers, including antisense oligonucleotides and small interfering RNA therapies, are established disease-modifying agents for variant transthyretin amyloidosis (ATTRv) with polyneuropathy. The role of a small interfering RNA (vutrisiran) in TTR amyloid cardiomyopathy has already been shown in a randomized clinical trial, but only 6 patients had the “Portuguese” TTR variant (Val50Met). Moreover, there are no officially approved treatments specifically for mixed phenotypes. Our study describes real-world experience in a cohort of patients with Val50Met ATTRv with a neurologic indication for having been treated with TTR silencers, who had coexisting confirmed amyloid cardiomyopathy (AC).</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:11.0pt">Methods: </span></strong><span style="font-size:11.0pt">We performed a single-centre retrospective study including all patients with Val50Met TTR variant followed at our Cardiology clinic who were treated with TTR silencers due to their polyneuropathy, but who also had diagnosed AC, ergo a mixed phenotype. Baseline clinical, laboratory and echocardiographic data were collected. Patients with ≥2 visits while on therapy were included in the follow-up analysis. Cardiac stabilisation was defined as <30% increase in NT-proBNP, <5% absolute decrease in left ventricular ejection fraction (LVEF), and <2 mm increase in wall thickness.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:11.0pt">Results: </span></strong><span style="font-size:11.0pt">Thirty-seven patients were enrolled (67.6% male; median age 66 years). Most patients (78.4%) had received tafamidis 20 mg before starting a silencer. Initial treatment consisted of patisiran (70.3%), inotersen (18.9%) or vutrisiran (10.8%). Twenty-seven patients met criteria for follow-up (mean 29.5 months)</span><span style="font-size:11.0pt">. Echocardiographic stability was observed in 74.1% for wall thickness and 66.7% for LVEF, and NT-proBNP stability was achieved in 81.5%; overall cardiac stabilisation was seen in 51.9%. NYHA class remained stable or improved in most patients, with 11.1% worsening; diuretic therapy was initiated or intensified in 22.2% patients. New pacemaker implantation occurred in 22.2% cases and new atrial arrhythmias in 11.1%.<strong> </strong>No heart failure hospitalisations or organ transplants occurred, and 11.1% patients died during follow-up.</span></span></span></p> <p style="text-align:center"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:11.0pt">Discussion and conclusions: </span></strong><span style="font-size:11.0pt">In this real-world cohort of patients with Val50Met vATTR, TTR silencers were associated with stabilisation of key structural, functional and biomarker parameters in 51% of the patients, alongside a favourable overall clinical trajectory in most. These findings support a potential role for RNA-silencing therapy in patients with mixed phenotype ATTRv amyloidosis, although larger prospective studies are needed. Expanding data about transthyretin hereditary and wild-type amyloidosis may refine future management of cardiac disease in these patients.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site